Interview: Jaw-Jou Kang, former Director General, Taiwan Food & Drug…
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
Address: No.161-2, Kunyang St., Nangang Dist., Taipei City 115, Taiwan
Tel: (02) 2787-8000
Web: http://www.fda.gov.tw/TC/index.aspx
As food, drugs, and cosmetics are intensively involved in people’s daily life and health as well as medical welfare, the Department of Health has strived to facilitate organizational reformation with its focus placed upon consumer health in terms of food and drug safety. Consolidation of the Bureau of Food Safety, the Bureau of Pharmaceutical Affairs, the Bureau of Food and Drug Analysis and the Bureau of Controlled Drugs into the Taiwan Food and Drug Administration (TFDA) was completed on January 1st, 2010, following the promulgation of the TFDA Organization Act on June 3rd, 2009.
Such organizational reformation tends to streamline the process from policy planning to execution, and to increase administration efficiency. Information relating to food and drug safety is released to the public more swiftly, allowing consumers safe and quality food and drugs. TFDA will endeavor to meet the vision to safeguard national health and lead the nation to a new era of food and drug management.
Vision
The vision of TFDA is to safeguard national health and lead the nation to a new era of food and drug management.
Mission
TFDA has the missions to safeguard food and drug safety, to begin a new technology era, and to create a safe consumer environment.
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
In January 2010, the Taiwan FDA was newly created from four existing agencies. What was the vision behind the creation of this new organisation? What did the government want to…
As President of the Taiwan Clinical Research Association (TCRA), Tina Sun brings 25 years of pharmaceutical industry experience to bear on the evolution of Taiwan’s clinical research ecosystem. This interview…
Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the…
Taiwan is entering a pivotal phase in its healthcare evolution, and Roche’s leaders in Taiwan outline how the convergence of global expertise, advanced diagnostics and innovative therapeutics can accelerate that…
Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing…
Lian-Yu Chen, Director General of Taiwan’s National Health Insurance Administration, combines expertise in clinical psychiatry, public health, and governmental leadership. A PhD graduate of Johns Hopkins Bloomberg School of Public…
Under Dave Huang’s leadership, Ferring Taiwan has evolved from organisational recovery to sustained performance and regional relevance. The discussion that follows examines how disciplined focus, early engagement with innovation, and…
Hung Lai Wu, Chairperson of the Taiwan Alliance of Patients’ Organisations (TAPO) and a home dialysis patient for 18 years, has transformed personal experience into systemic advocacy. Since becoming a…
Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She…
How leadership choices translate into lasting impact is the central theme of this conversation with Grant Hu. From reshaping Eisai Taiwan’s organisation to navigating access, innovation, and policy engagement, the…
Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech,…
PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren…
Yenchen Huang, Head of Investment, VP at Diamond Biofund, one of Taiwan’s pioneering evergreen venture capital funds focused on life sciences, our interviewee brings a unique perspective combining scientific training…
See our Cookie Privacy Policy Here
